Sign in
CompletedPhase 4

Perioperative Nitric Oxide Prevents Acute Kidney Injury in Acute Type A Aortic Dissection Patients

Key facts

Who runs it
Beijing Anzhen Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
106 people enrolled
Started
30 Nov 2024
Ended
2 Feb 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Nitric Oxide
  • Placebo
Record updated
5 February 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Provide written informed consent
  • Participants must be over 18 years of age
  • Participants should meet the diagnostic and treatment guidelines for thoracic aortic diseases jointly issued by ACC/AHA in 2022, have received clinical and radiological diagnosis of acute type A aortic dissection, and undergone surgical thoracotomy within two weeks after symptom onset

Who cannot take part

  • Previous renal tumor, kidney transplantation, and other related surgery
  • History of kidney disease, including glomerular diseases: acute glomerulonephritis, rapidly progressive glomerulonephritis, chronic glomerulonephritis, nephrotic syndrome, etc., secondary nephropathy: lupus nephritis, diabetic nephropathy, interstitial nephritis, renal tubular disease, chronic renal failure, renal replacement therapy, etc
  • History of malignant tumor or received radiotherapy and chemotherapy
  • Severe skeletal muscle disease and autoimmune disease
  • Pregnant and lactating women, patients with mental disorders
  • With intravascular or extravascular hemolytic disease
  • Missing baseline value or missing postoperative serum creatinine value (Scr)
  • Preoperative eGFR less than 30ml/min/1.73m2 or receive renal replacement therapy
  • Patients with single kidney
  • Preoperative dissection rupture or hemodynamic instability (systolic blood pressure <90mmHg)
  • Life expectancy less than 90 days
  • Have participated in other clinical trials

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to determine the effectiveness of exogenous nitric oxide therapy in reducing the occurrence of acute kidney injury in patients with acute type A aortic dissection. Additionally, it aims to assess the safety of exogenous nitric oxide therapy.

The 2 groups in the trial

  • Nitric OxideTreatment being tested

    Patients in this group receive treatment with exogenous nitric oxide (NO) via the CPB machine. After CPB, NO is administered through the inspiratory limb of the anesthetic or ventilator circuit and then via the mechanical ventilator in the ICU. Once patients are extubated, they will breathe NO through a facemask or nasal cannula. NO administration begins at the start of CPB and continues for 12 hours post-operation.

  • Usual carePlacebo, for comparison

    Patients in this group receive a sham treatment without the supply of nitric oxide during CPB and for 12 hours post-operation.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Nitric Oxide Administration for Reducing the Risk of Acute Kidney Injury in Patients With Acute Type A Aortic Dissection: a Randomized Controlled Trial
Publications
Record updated
5 February 2026